BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 07, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Brentuximab vedotin: Phase I/II data

Seattle Genetics reported retreatment data from 7 CD30+ Hodgkin's lymphoma or systemic anaplastic large cell lymphoma (ALCL) patients who had achieved stable disease, but relapsed after discontinuing brentuximab treatment in 1 of 3 Phase I and II trials. Eight retreatment experiences...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >